Nitromed, Inc. Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 7 Calls Today's Calls

Call Details Nitromed, Inc. Earnings Conference Call (Q1 2008) Wed, May 7, 2008, 8:00 am Eastern Listen to the archived event audio About Nitromed, Inc. (NasdaqGM:NTMD) Other Calls  NitroMed, Inc. manufactures BiDil, an orally administered medicine for the treatment of heart failure in self-identified black patients. BiDil is a combination of isosorbide dinitrate and hydralazine hydrochloride. The company is also developing an extended release formulation of BiDil, known as BiDil XR. It has a license agreement with Elan Pharma International Limited to import, use, and sell an oral capsule formulation incorporating specified technology owned or controlled by Elan and containing the combination of isosorbide dinitrate and hydralazine hydrochloride. The company was founded in 1992 and is based in Lexington, Massachusetts. More Info: Quote | Chart | News | Profile | Reports | Research | Msgs | Insider | Financials | Analyst Ratings